Compare C3.ai Inc (AI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C3.ai Inc vs Merck & Co., Inc. — how do they compare? C3.ai Inc trades at $11.13 (market cap $1.77B), while Merck & Co., Inc. trades at $143.72 (market cap $358.50B). The key difference: Merck & Co., Inc. is far larger — about 202.5× C3.ai Inc's market cap, and Merck & Co., Inc. pays a 2.34% dividend while C3.ai Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold C3.ai Inc for 136 Days and Merck & Co., Inc. for 98 Days on average.
| AI | MRK | |
|---|---|---|
Market Cap | $1.77B | $358.50B |
Volume | 5,310,546 | 10,180,803 |
Sector | Technology | Health |
52-Week High | $19.66 | $156.43 |
52-Week Low | $7.76 | $82.49 |
Typical Hold Time | 136 Days | 98 Days |
Enterprise Value | $1.12B | $405.27B |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai stock trades at $11.045, up 6.1% in 24 hours, with a bearish technical signal. The company reported revenue of $389.06M in 2025 but a net loss of $288.70M, with negative margins persisting. Recent news highlights CEO and CFO stock sales, while analyst consensus is mixed with a $9.67 price target below the current price.
Outlook remains challenged by sustained losses and cash burn, though recent quarterly EPS beats offer some optimism. Key risks include high valuation multiples amid unprofitability and insider selling. Investment opportunity hinges on future profitability improvements and AI sector tailwinds.
Merck (MRK) trades at $144.13, down 3.48% on the day, amid a mixed technical and fundamental backdrop. The stock shows bullish moving average signals but neutral oscillators, with support near $140. Financially, MRK reported $65.01B revenue in 2025 with a net income margin of 4.77%, though its P/E ratio of 116.25 reflects high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, signaling strategic growth efforts.
The outlook for MRK is cautiously optimistic, supported by strong analyst buy ratings (68% consensus) and a $159.59 price target. Key opportunities include pipeline expansion via M&A and solid cash flow, while risks involve elevated debt levels and competitive pressures in pharma. Investors should weigh growth initiatives against valuation concerns and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
